NC
HRTX icon

NewSquare Capital’s Heron Therapeutics HRTX Stock Holding History

NewSquare Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40
Closed -$46 – 721
2023
Q2 		$46 Hold
40
– – ﹤0.01% 819
2023
Q1 		$60 Hold
40
– – ﹤0.01% 844
2022
Q4 		$100 Buy
+40
New +$129 ﹤0.01% 770
2018
Q3 		– Sell
-5,420
Closed -$211K – 324
2018
Q2 		$211K Buy
+5,420
New +$173K 0.04% 104

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

NewSquare Capital's HRTX Position: Q3 2023 in Review

NewSquare Capital sold out of Heron Therapeutics (HRTX) in Q3 2023, closing a stake of 40 shares — an estimated $46 sold.

NewSquare Capital first reported a position in HRTX in Q2 2018 and held it in 4 quarters. The position peaked at $211K in Q2 2018. 141 funds tracked by Wall St. Rank hold HRTX as of Q3 2023.

  • NewSquare Capital reported no remaining Heron Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 40 Heron Therapeutics shares in Q3 2023, an estimated $46.
  • NewSquare Capital first reported a position in Heron Therapeutics in Q2 2018 and held it in 4 quarters.
  • NewSquare Capital's Heron Therapeutics position peaked at $211K in Q2 2018.
  • 141 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.